Other languages Agenus Inc.

Equities

AGEN

US00847G8042

Real-time Estimate Cboe BZX Other stock markets 20:06:15 02/05/2024 BST			5-day change	1st Jan Change
12.83 ^USD	-3.24%		+57.23%	-21.19%

04-12	Sector Update: Health Care Stocks Slipping Late Afternoon	MT
04-12	Sector Update: Health Care	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Slipping Late Afternoon	04-12
Sector Update: Health Care	04-12
Agenus Shares Decline After Update on Early Stage Colorectal Cancer Drug Trial	04-12
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	04-12
Agenus Stockholders Approve 1-for-20 Reverse Stock Split	04-05
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14
Agenus Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14
Agenus Inc. Announces Preclinical Data on BMS-986442 at AACR 2024	03-06
Ginkgo Bioworks, Agenus Unit Win Contract to Discover, Develop Vaccine Adjuvants	02-15
Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer	12-20
Agenus to Get $25 Million Milestone Payment From Bristol Myers Squibb Under AGEN1777 Licensing Deal	12-11
Agenus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07
Agenus Inc. Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma	22/10/23
Agenus Inc. Announces Expanded Data from the Company's Phase 1B Study of Botensilimab in Combination with Balstilimab (Bal, Anti-Pd-1) in Patients with Advanced Sarcomas	21/10/23
Agenus Completes Patient Enrollment in Phase 2 Trial of Colorectal Cancer Therapy	10/10/23
Agenus Inc. Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer	10/10/23
Agenus to Lay Off 25% of Workforce for Expected Savings of $2.8 Million	23/08/23
Agenus Inc. Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers	23/08/23
Agenus Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23
Agenus Reports Survival Benefits in Early-Stage Combo Trial in Colorectal Cancer	30/06/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Agenus Inc.

Equities

AGEN

US00847G8042

Other languages

Filters